Diving into the intricate world of cancer biology, we’re thrilled to speak with Ivan Kairatov, a renowned biopharma expert with a profound background in research and development. With a sharp focus on technological innovation in the industry, Ivan has been at the forefront of uncovering how
Imagine a world where the intricate dance of molecules within the brain can be captured in stunning detail, offering a roadmap to tackle one of neurology’s most persistent challenges—epilepsy. This vision is becoming reality thanks to cryo-electron microscopy (Cryo-EM), a cutting-edge technology
Imagine a simple shot, one already familiar to millions for preventing a painful skin condition, holding the power to shield the mind from a devastating disease like dementia—a condition impacting over 55 million people worldwide with no cure in sight. That’s the startling promise emerging from a
Imagine a woman in her late 60s, recently retired, enjoying her newfound freedom, only to face a devastating diagnosis of breast cancer. What if something as seemingly controllable as her weight could have dramatically altered her risk? This scenario is becoming all too common, as research reveals
Rising failure rates for single-mechanism therapies in heterogeneous solid tumors have pushed oncology beyond single-target tinkering and into platform-centric thinking that prizes modularity, combinability, and consistent manufacturability across programs. In this shift, antibody-drug conjugates
Ivan Kairatov has spent years at the crossroads of oncology and drug development, translating trial signals into day-to-day decisions for patients with localized prostate cancer. In this conversation, he unpacks new evidence showing that most of the value from androgen deprivation therapy (ADT)
